Europe Asthma Drugs Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Medication (Quick Relief Medications and Long-Term Control Medications), Route of Administration (Inhaled, Prefilled Syringe/Vials, and Others), and Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies)
The Europe asthma drugs market is expected to reach US$ 9,636.62 million by 2028 from US$ 6,876.65 million in 2021; it is estimated to grow at a CAGR of 4.9% from 2021 to 2028.
The growth of the market is attributed to the rising prevalence of asthma and the growing exposure to coarse particulate matters. However, the unmet medical needs hamper the market growth.
Asthma is a disorder in which psychological elements have played a significant role since the 20th century. Clinicians understand that emotional stress can trigger or exacerbate asthma and that a patient's mental health can impair asthma control by influencing symptom presentation and treatment adherence. As a result, there is a bi-directional link between asthma and psychological issues.
Asthmatics and asthma exacerbations are associated with periods of heightened emotionality. Depressive disorders are more common among people with asthma than in the general population, according to various prevalence estimates, some of which reach 40%. Patients with bipolar affective disorders tend to have a higher chance of acquiring IgE-mediated allergy diseases, such as asthma, than the general population. Anxiety disorders also have an elevated prevalence in asthma, affecting up to one-third of asthmatic children and adolescents and 24% of asthmatic adults.
Ambiguous disease criteria, inconsistencies in nomenclature, limited samples, and an emphasis on outpatient or inpatient population rather than the community affects the research on the frequency of psychological and mental disorders in asthmatics. The World Mental Health Survey addresses a few of these methodological issues by providing standardized data for 17 nations across the world. Compared to individuals without asthma, the pooled estimates of age- and sex-adjusted odds of mental disorders were 1.6 (95% CI=1.4, 1.8) for depressive disorders and 1.5 (95% CI=1.4,1.7) for anxiety disorders. There was also a link between asthma and alcohol use disorders (OR 1.7 (95% CI=1.4, 2.1) in this study.
Although the frequency of mental disorders and asthma varies substantially between nations, there was much less cross-sectional heterogeneity in their connection. Given that the countries represented varied greatly in terms of culture, healthcare organization, and socioeconomic development, this constancy is remarkable. It suggests that practitioners in any environment should be aware of the extensive overlap between asthma and psychological and mental illnesses.
Early psychosomatic models suggested that psychological discomfort played a role in varying asthma morbidity among asthma patients. However, emerging knowledge of pathophysiological pathways indicated that psychological variables might also play a role in the genesis of asthma. The disruption of critical biological systems such as the neuroendocrine stress response, cytokines, and neuropeptides is similar to asthma and serious depressive disorders. Additional evidence of a genetic relationship between atopic and depressed symptoms comes from twin-pair studies.
Because of the link between asthma and psychological issues, psychological therapies are occasionally employed to supplement pharmaceutical asthma care. Behavioral therapies, cognitive therapies, cognitive-behavioral therapies (CBT), relaxation techniques, psycho-dynamic psychotherapies, and counseling (both for the person and the family) have all been tried. Unlike pharmacological asthma treatments, there is still a lack of evidence regarding the effectiveness of psychosocial therapy in children and adults. This is expected to boost the need for asthma treatments in the coming years, driving the European asthma drugs market.
Europe Asthma Drugs Market Revenue and Forecast to 2028 (US$ Mn)
Get more information on this report :
Europe Asthma Drugs Market Segmentation
The Europe asthma drugs market, by medication, is segmented into quick relief medications and long-term control medications. Based on route of administration, the market is segmented into inhaled, prefilled syringe/vials, and others. Based on distribution channel, the Europe asthma drugs market is segmented into online pharmacies, hospital pharmacies, and retail pharmacies. By country, the market is segmented into the Germany, Spain, Italy, France, UK and Rest of Europe.
AstraZeneca; TEVA PHARMACEUTICAL INDUSTRIES LTD; Boehringer Ingelheim International GmbH; GlaxoSmithKline plc.; Merck & Co., Inc.; Koninklijke Philips N.V.; Sanofi; Pfizer Inc. (Arena Pharmaceutical GmbH); Novartis AG; and Abbott are among the leading companies operating in the Europe asthma drugs market.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Asthma Drugs Market – By Medication
1.3.2 Europe Asthma Drugs Market – By Route of Administration
1.3.3 Europe Asthma Drugs Market – By Distribution Channel
1.3.4 Europe Asthma Drugs Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Asthma Drugs Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Europe – PEST Analysis
4.3 Expert Opinion
5. Asthma Drugs Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Environmental Implications & Genetic Implications of Air Pollution
5.1.2 Growing Prevalence of Physiological Disorders Harboring Asthma
5.2 Market Restraints
5.2.1 Unmet Medical Needs
5.3 Market Opportunities
5.3.1 Opportunities with Commercialization of Biologics
5.4 Future Trends
5.4.1 Increasing Research Activities and Product Innovations
5.5 Impact Analysis
6. Asthma Drugs Market– Europe Analysis
6.1 Europe Asthma Drugs Market Revenue Forecast and Analysis
7. Asthma Drugs Market Analysis – by Medication
7.1 Overview
7.2 Asthma Drugs Market Revenue Share, by Medication (2021 and 2028)
7.3 Quick Relief Medications
7.3.1 Overview
7.3.2 Quick Relief Medications: Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Long-term Control Medications
7.4.1 Overview
7.4.2 Long-term Control Medications: Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
8. Asthma Drugs Market Analysis – By Route of Administration
8.1 Overview
8.2 Asthma Drugs Market Revenue Share, By Route of Administration (2021 and 2028)
8.3 Inhaled
8.3.1 Overview
8.3.2 Inhaled: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
8.4 Prefilled Syringe/Vials
8.4.1 Overview
8.4.2 Prefilled Syringe/Vials: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
8.5 Others (Oral, Nasal, Ophthalmic Etc.)
8.5.1 Overview
8.5.2 Others: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
9. Asthma Drugs Market Analysis – By Distribution Channel
9.1 Overview
9.2 Asthma Drugs Market Revenue Share, By Distribution Channel (2021 and 2028)
9.3 Online Pharmacies
9.3.1 Overview
9.3.2 Online Pharmacies: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
9.4 Hospital Pharmacies
9.4.1 Overview
9.4.2 Hospital Pharmacies: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
9.5 Retail Pharmacies and Drugstores
9.5.1 Overview
9.5.2 Retail Pharmacies and Drugstores: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
10. Asthma Drugs Market – Europe Analysis
10.1 Europe
10.1.1 Overview
10.1.2 Europe: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
10.1.3 Europe: Asthma Drugs Market, by Medication, 2019–2028 (USD Million)
10.1.4 Europe: Asthma Drugs Market, by Route of Administration, 2019–2028 (USD Million)
10.1.5 Europe: Asthma Drugs Market, by Distribution Channel, 2019–2028 (USD Million)
10.1.6 Europe: Asthma Drugs Market, by Country, 2021 & 2028 (%)
10.1.6.1 Germany: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.1.1 Germany: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.1.2 Germany: Asthma Drugs Market, by Medication, 2019–2028 (USD Million)
10.1.6.1.3 Germany: Asthma Drugs Market, by Route of Administration, 2019–2028 (USD Million)
10.1.6.1.4 Germany: Asthma Drugs Market, by Distribution Channel, 2019–2028 (USD Million)
10.1.6.2 UK: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.2.1 UK: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.2.2 UK: Asthma Drugs Market, by Medication, 2019–2028 (USD Million)
10.1.6.2.3 UK: Asthma Drugs Market, by Route of Administration, 2019–2028 (USD Million)
10.1.6.2.4 UK: Asthma Drugs Market, by Distribution Channel, 2019–2028 (USD Million)
10.1.6.3 France: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.3.1 France: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.3.2 France: Asthma Drugs Market, by Medication, 2019–2028 (USD Million)
10.1.6.3.3 France: Asthma Drugs Market, by Route of Administration, 2019–2028 (USD Million)
10.1.6.3.4 France: Asthma Drugs Market, by Distribution Channel, 2019–2028 (USD Million)
10.1.6.4 Italy: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.4.1 Italy: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.4.2 Italy: Asthma Drugs Market, by Medication, 2019–2028 (USD Million)
10.1.6.4.3 Italy: Asthma Drugs Market, by Route of Administration, 2019–2028 (USD Million)
10.1.6.4.4 Italy: Asthma Drugs Market, by Distribution Channel, 2019–2028 (USD Million)
10.1.6.5 Spain: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.5.1 Spain: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.5.2 Spain: Asthma Drugs Market, by Medication, 2019–2028 (USD Million)
10.1.6.5.3 Spain: Asthma Drugs Market, by Route of Administration, 2019–2028 (USD Million)
10.1.6.5.4 Spain: Asthma Drugs Market, by Distribution Channel, 2019–2028 (USD Million)
10.1.6.6 Rest of Europe: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.6.1 Rest of Europe: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.6.2 Rest of Europe: Asthma Drugs Market, by Medication, 2019–2028 (USD Million)
10.1.6.6.3 Rest of Europe: Asthma Drugs Market, by Route of Administration, 2019–2028 (USD Million)
10.1.6.6.4 Rest of Europe: Asthma Drugs Market, by Distribution Channel, 2019–2028 (USD Million)
11. Asthma Drugs Market–Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 AstraZeneca
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 GlaxoSmithKline plc.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Boehringer Ingelheim International GmbH
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Merck & Co., Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Koninklijke Philips N.V.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Sanofi
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Pfizer Inc. (Arena Pharmaceutical GmbH)
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Novartis AG
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Abbott
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. Odds Ratio (OR) For Mental Disorders among Adults with Asthma Vs Without Asthma
Table 2. Asthma Death Rates for Select Countries, 2018
Table 3. Common SABAs
Table 4. Commonly inhaled corticosteroids
Table 5. Europe: Asthma Drugs Market, by Medication – Revenue and Forecast to 2028 (USD Million)
Table 6. Europe: Asthma Drugs Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 7. Europe: Asthma Drugs Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 8. Germany: Asthma Drugs Market, by Medication – Revenue and Forecast to 2028 (USD Million)
Table 9. Germany: Asthma Drugs Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 10. Germany: Asthma Drugs Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 11. UK: Asthma Drugs Market, by Medication – Revenue and Forecast to 2028 (USD Million)
Table 12. UK: Asthma Drugs Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 13. UK: Asthma Drugs Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 14. France: Asthma Drugs Market, by Medication – Revenue and Forecast to 2028 (USD Million)
Table 15. France: Asthma Drugs Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 16. France: Asthma Drugs Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 17. Italy: Asthma Drugs Market, by Medication – Revenue and Forecast to 2028 (USD Million)
Table 18. Italy: Asthma Drugs Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 19. Italy: Asthma Drugs Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 20. Spain: Asthma Drugs Market, by Medication – Revenue and Forecast to 2028 (USD Million)
Table 21. Spain: Asthma Drugs Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 22. Spain: Asthma Drugs Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 23. Rest of Europe: Asthma Drugs Market, by Medication – Revenue and Forecast to 2028 (USD Million)
Table 24. Rest of Europe: Asthma Drugs Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 25. Rest of Europe: Asthma Drugs Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 26. Organic Developments in the Asthma Drugs Market
Table 27. Inorganic Developments in the Asthma Drugs Market
Table 28. Glossary of Terms, Asthma Drugs Market
LIST OF FIGURES
Figure 1. Asthma Drugs Market Segmentation
Figure 2. Asthma Drugs Market, By Country
Figure 3. Europe Asthma Drugs Market Overview
Figure 4. The Long Term Control Medications Segment Held Largest Share of Mode of Service in the Asthma Drugs Market
Figure 5. EuropeAsthma Drugs Market- Leading Country Markets (US$ Million)
Figure 6. Europe PEST Analysis
Figure 7. Expert Opinion
Figure 8. Impact of Low Mood/Anxiety on Asthma
Figure 9. Asthma Drugs Market Impact Analysis of Drivers and Restraints
Figure 10. Europe Asthma Drugs Market– Revenue Forecast and Analysis – 2020- 2028
Figure 11. Asthma Drugs Market Revenue Share, by Medication (2021 and 2028)
Figure 12. Quick Relief Medications: Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Long-term Control Medications: Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Asthma Drugs Market Share, By Route of Administration, 2021 and 2028 (%)
Figure 15. Inhaled: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
Figure 16. Prefilled Syringe/Vials: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
Figure 17. Others: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
Figure 18. Asthma Drugs Market Share, By Distribution Channel, 2021 and 2028 (%)
Figure 19. Online Pharmacies: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
Figure 20. Hospital Pharmacies: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
Figure 21. Retail Pharmacies and Drugstores: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
Figure 22. Europe: Asthma Drugs Market, by Key Country – Revenue (2021) (USD Million)
Figure 23. Europe: Asthma Drugs Market Revenue and Forecast to 2028 (USD Million)
Figure 24. Europe: Asthma Drugs Market, by Country, 2021 & 2028 (%)
Figure 25. Germany: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
Figure 26. UK: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
Figure 27. France: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
Figure 28. Italy: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
Figure 29. Spain: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
Figure 30. Rest of Europe: Asthma Drugs Market – Revenue and Forecast to 2028 (USD Million)
- AstraZeneca
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- GlaxoSmithKline plc.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline plc.
- Merck & Co., Inc.
- Koninklijke Philips N.V.
- Sanofi
- Pfizer Inc. (Arena Pharmaceutical GmbH)
- Novartis AG
- Abbott
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe asthma drugs market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe asthma drugs market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.